Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21353855 | 0.79 | AOC3 (0.47) | AOC3KDM4EIGF1RMEN1KMT2A | |
| SCHEMBL31378985 | 0.79 | AOC3 (0.47) | AOC3KDM4EIGF1RHTTGABBR2 | |
| SCHEMBL7104502 | 0.79 | AOC3 (0.47) | AOC3KDM4EIGF1RMEN1KMT2A | |
| SCHEMBL27417198 | 0.79 | AOC3 (0.52) | AOC3GABBR2GABBR1IDO1 | |
| SCHEMBL12503320 | 0.78 | AOC3 (0.46) | AOC3KDM4EIGF1RMEN1KMT2A | |
| SCHEMBL11555282 | 0.77 | AOC3 (0.36) | AOC3KDM4EHTTTRPA1IDO1 | |
| SCHEMBL2632364 | 0.76 | LMNA (0.60) | AOC3KDM4EIGF1RMEN1KMT2A | |
| SCHEMBL1978021 | 0.76 | LMNA (0.60) | AOC3KDM4EIGF1RMEN1KMT2A | |
| SCHEMBL14569262 | 0.76 | LMNA (0.60) | AOC3KDM4EIGF1RMEN1KMT2A | |
| SCHEMBL7928876 | 0.75 | DPP4 (0.41) | AOC3GABBR2GABBR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | claimed |
| CN-104603104-B | Crystal formation of azetidine ketonic compound and preparation method thereof | 浙江海正药业股份有限公司 | 2016-12-07 | — | — | CN | disclosed |
| US-6486173-B2 | SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | disclosed |
| US-6239143-B1 | TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. | DUPONT PHARMACEUTICALS COMPANY | 2001-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | AOC3 1334/4885KDM4E 3671/4885IGF1R 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.